# Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

> **NCT00656799** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** sugammadex
- **DRUG:** Rocuronium

## Key facts

- **NCT ID:** NCT00656799
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656799, "Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00656799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*